However, molecular studies have demonstrated the co-expression of VEGFR, PDGFRB, RET, and MET and high PD-L1 expression in ASPS cells, which predict the favorable treatment response of multi-target AIs and ICIs8,13. This evidence concerns the gene PDGFRB and alveolar soft part sarcoma.